Federal Register / Vol. 83, No. 126 / Friday, June 29, 2018 / Notices 30757 

based integrated approach to opioid 

prevention and treatment services in a 

single community? 

Health Economics: 

• What economic questions should be 

included as part of the study to inform 

systems and policy change? 

Implementation Research: 

• What implementation research 

questions should be included to develop 

best practices for replication in other 

communities impacted by the opioid 

crisis? 

• What data should be collected to 

help develop metrics for determining 

the quality of an integrated approach to 

opioid prevention and treatment 

services, including policies and 

practices? 

• Are there examples of prior 

implementation research studies that 

highlight implementation tools that can 

be used to replicate and scale up 

integrated approaches? 

Infrastructure, Partnerships, 

Collaboration: 

• What research, prevention, and 

treatment infrastructure and 

partnerships are needed to support a 

community-based pragmatic trial 

assessing the impact of an evidencebased integrated approach to opioid 

prevention and treatment services? 

• What is the best approach to 

fostering collaboration and meaningful 

participation between state, county, and 

local governments; community 

stakeholders; medical/clinical service 

providers; and researchers? 

• How do we construct a research 

initiative with the highest likelihood of 

having sustainable prevention and 

treatment services? 

• What data would be of most interest 

to state and community partners? 

Responses to this RFI are voluntary 

and may be submitted anonymously. 

Please do not include any personally 

identifiable or other information that 

you do not wish to make public. 

Proprietary, classified, confidential, or 

sensitive information should not be 

included in responses. Comments 

submitted will be compiled for 

discussion and shared internally with 

NIDA, SAMHSA, NIH program staff, 

and participating leadership across the 

Department of Health and Human 

Services, as appropriate. Any personal 

identifiers (personal names, email 

addresses, etc.) will be removed when 

responses are compiled. 

This RFI is for informational and 

planning purposes only and is not a 

solicitation for applications or an 

obligation on the part of the United 

States Government to provide support 

for any ideas identified in response to 

it. Please note that the United States 

Government will not pay for the 

preparation of any information 

submitted or for use of that information. 

Dated: June 25, 2018. 

Lawrence A. Tabak, 

Deputy Director, National Institutes of Health. 

[FR Doc. 2018–14031 Filed 6–28–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; T1D NIDDK Review. 

Date: June 29, 2018. 

Time: 9:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Elena Sanovich, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7351, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–8886, 

sanoviche@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK–17–021: 

HIRN Consortium on Beta Cell Death and 

Survival Early T1D Biomarkers Discovery in 

Human Pancreas. 

Date: July 23, 2018. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; T1D Clinical Trials 

Testing Current and Novel Closed Loop 

Systems (R01). 

Date: July 24, 2018. 

Time: 3:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Jason D. Hoffert, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7343, 6707 Democracy Boulevard, 

Bethesda, MD 20817, 301–496–9010, 

hoffertj@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK–17–020: 

Immune System Engineering for Targeted 

Tolerance in Type 1 Diabetes (R01). 

Date: July 25, 2018. 

Time: 11:00 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Dianne Camp, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7013, 6707 Democracy Boulevard, 

Bethesda, MD 20892–2542, 301–594–7682, 

campd@extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; SBIR Phase II 

Clinical Trials. 

Date: July 26, 2018. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Thomas A. Tatham, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7021, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–3993, 

tathamt@mail.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–18–042: 

NIDDK Ancillary Studies (R01). 

Date: July 26, 2018. 

Time: 11:30 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Ann A. Jerkins, Ph.D., 

Scientific Review Officer, Review Branch, 


sradovich on DSK3GMQ082PROD with NOTICES
30758 Federal Register / Vol. 83, No. 126 / Friday, June 29, 2018 / Notices 

DEA, NIDDK, National Institutes of Health, 

Room 7119, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, 301–594–2242, 

jerkinsa@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; RFA–DK–17–022: 

High Resolution Exploration of the Human 

Islet Tissue Environment (HIRN)–HPAC. 

Date: July 30, 2018. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: June 25, 2018. 

David D. Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–13967 Filed 6–28–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; SBIR Contract Review. 

Date: July 25, 2018. 

Time: 1:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, One 

Democracy Plaza, Room 1087, 6701 

Democracy Boulevard, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Rahat (Rani) Khan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, 6701 Democracy 

Blvd., Rm 1078, Bethesda, MD 20892, 301– 

594–7319, khanr2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: June 25, 2018. 

David D. Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–13966 Filed 6–28–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2018–0025; OMB No. 

1660–0040] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request; Standard Flood 

Hazard Determination Form 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice and request for 

comments. 

SUMMARY: The Federal Emergency 

Management Agency, as part of its 

continuing effort to reduce paperwork 

and respondent burden, invites the 

general public to take this opportunity 

to comment on an extension, without 

change, of a currently approved 

information collection. In accordance 

with the Paperwork Reduction Act of 

1995, this notice seeks comments 

concerning this form which is used by 

regulated lending institutions, federal 

agency lenders, the Federal National 

Mortgage Association, the Federal Home 

Loan Mortgage Corporation, and the 

Government National Mortgage 

Association. Federally regulated lending 

institutions complete this form when 

making, increasing, extending, renewing 

or purchasing each loan for the purpose 

is of determining whether flood 

insurance is required and available. 

FEMA is responsible for maintaining the 

form and making it available. 

DATES: Comments must be submitted on 

or before August 28, 2018. 

ADDRESSES: To avoid duplicate 

submissions to the docket, please use 

only one of the following means to 

submit comments: 

(1) Online. Submit comments at 

www.regulations.gov under Docket ID 

FEMA–2018–0025. Follow the 

instructions for submitting comments. 

(2) Mail. Submit written comments to 

Docket Manager, Office of Chief 

Counsel, DHS/FEMA, 500 C Street SW, 

8NE, Washington, DC 20472–3100. 

All submissions received must 

include the agency name and Docket ID. 

Regardless of the method used for 

submitting comments or material, all 

submissions will be posted, without 

change, to the Federal eRulemaking 

Portal at http://www.regulations.gov, 

and will include any personal 

information you provide. Therefore, 

submitting this information makes it 

public. You may wish to read the 

Privacy Act notice that is available via 

the link in the footer of 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Susan Bernstein, Insurance Specialist, 

FIMA, Marketing and Outreach Branch, 

303–701–3595. You may contact the 

Information Management Division for 

copies of the proposed collection of 

information at email address: FEMAInformation-Collections-Management@

fema.dhs.gov. 

SUPPLEMENTARY INFORMATION: Section 

1365 of the National Flood Insurance 

Act of 1968 (NFIA) (42 U.S.C. 4104b), as 

added by Section 528 of the National 

Flood Insurance Reform Act of 1994 

(Pub. L. 103–325, title V), requires that 

FEMA develop a standard hazard 

determination form for recording the 

determination of whether a structure is 

located within an identified Special 

Flood Hazard Area and whether flood 

insurance is available. Regulated 

lending institutions, federal agency 

lenders, the Federal National Mortgage 

Association, the Federal Home Loan 

Mortgage Corporation, and the 

Government National Mortgage 

Association must complete this form for 

any loan made, increased, extended, 

renewed or purchased by these entities. 

The requirement for federally regulated 

lending institutions to determine 

whether a building or mobile home 

securing a loan is located in an area 

having special flood hazards and 

whether flood insurance is available has 

been in effect since the enactment of the 

Flood Disaster Protection Act of 1973, 

although the use of a standard form was 

not required until the enactment of the 

Section 1365 of the NFIA. The 

establishment of the Standard Flood 

Hazard Determination form has enabled 


sradovich on DSK3GMQ082PROD with NOTICES